Type 1 diabetes(T1D)is an autoimmune disease characterized by the destruction of insulin-producingβ-cells of the pancreatic islets by autoreactive T cells,leading to high blood glucose levels and severe long-term com...Type 1 diabetes(T1D)is an autoimmune disease characterized by the destruction of insulin-producingβ-cells of the pancreatic islets by autoreactive T cells,leading to high blood glucose levels and severe long-term complications.The typical treatment indicated in T1D is exogenous insulin administration,which controls glucose levels;however,it does not stop the autoimmune process.Various strategies have been implemented aimed at stoppingβ-cell destruction,such as cellular therapy.Dendritic cells(DCs)as an alternative in cellular therapy have gained great interest for autoimmune disease therapy due to their plasticity to acquire immunoregulatory properties both in vivo and in vitro,performing functions such as anti-inflammatory cytokine secretion and suppression of autoreactive lymphocytes,which are dependent of their tolerogenic phenotype,displayed by features such as semimature phenotype,low surface expression of stimulatory molecules to prime T cells,as well as the elevated expression of inhibitory markers.DCs may be obtained and propagated easily in optimal amounts from peripheral blood or bone marrow precursors,such as monocytes or hematopoietic stem cells,respectively;therefore,various protocols have been established for tolerogenic(tol)DCs manufacturing for therapeutic research in the treatment of T1D.In this review,we address the current advances in the use of tolDCs for T1D therapy,encompassing protocols for their manufacturing,the data obtained from preclinical studies carried out,and the status of clinical research evaluating the safety,feasibility,and effectiveness of tolDCs.展开更多
基金A basic science grant from CONACyT,No.285480the Department of Clinical Immunology Research of the Biochemical Sciences Faculty.
文摘Type 1 diabetes(T1D)is an autoimmune disease characterized by the destruction of insulin-producingβ-cells of the pancreatic islets by autoreactive T cells,leading to high blood glucose levels and severe long-term complications.The typical treatment indicated in T1D is exogenous insulin administration,which controls glucose levels;however,it does not stop the autoimmune process.Various strategies have been implemented aimed at stoppingβ-cell destruction,such as cellular therapy.Dendritic cells(DCs)as an alternative in cellular therapy have gained great interest for autoimmune disease therapy due to their plasticity to acquire immunoregulatory properties both in vivo and in vitro,performing functions such as anti-inflammatory cytokine secretion and suppression of autoreactive lymphocytes,which are dependent of their tolerogenic phenotype,displayed by features such as semimature phenotype,low surface expression of stimulatory molecules to prime T cells,as well as the elevated expression of inhibitory markers.DCs may be obtained and propagated easily in optimal amounts from peripheral blood or bone marrow precursors,such as monocytes or hematopoietic stem cells,respectively;therefore,various protocols have been established for tolerogenic(tol)DCs manufacturing for therapeutic research in the treatment of T1D.In this review,we address the current advances in the use of tolDCs for T1D therapy,encompassing protocols for their manufacturing,the data obtained from preclinical studies carried out,and the status of clinical research evaluating the safety,feasibility,and effectiveness of tolDCs.
